The global Lanreotide market is expected to grow at a significant CAGR during the forecast period (2021-2027). Lanreotide injection is used to treat patients who have acromegaly and who have not responded to surgery or radiation. Lanreotide injection is also used to treat patients who have neuroendocrine tumours of the GI tract or pancreas (GEP-NETs) that have spread or cannot be removed surgically. Lanreotide injection belongs to the somatostatin agonist family of drugs. It works by lowering the number of specific hormones that the body produces.

According to the American Association of Neurological Surgeons, Cushing's disease affects around 10-15 million people each year. Furthermore, the condition primarily affects people aged 20 to 50 years old, with females having a higher prevalence than males. Furthermore, according to NCBI in 2018, the global prevalence of acromegaly is around 4,600 per million people. Acromegaly is also seen in about 116.9 new cases per million per year across the world. Thus the rising incidences of such rare diseases act as a driver for the global Lanreotide market.

Another important driver to the overall market growth is the availability of attractive government insurance plans and programmes for people with rare illnesses. For instance, several government healthcare institutions in the US and Europe, like the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), provide subsidised medications for rare disorders.

Furthermore, in June 2019, the US Food and Drug Administration (FDA) authorised a new pre-filled syringe for Somatuline Depot (lanreotide)  of Ipsen Biopharmaceuticals, a subsidiary of Ipsen. The syringe has been modified with new features such as bigger flanges to make injection administration easier for healthcare practitioners.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type

o By Outlook

o By Application

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Ipsen Pharmaceuticals, Bachem AG, AmbioPharm, ChemWerth Inc., Techland Corporation, 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lanreotide Market by Segments

By Type

• 60mg
• 90mg
• 120mg

By Outlook

• Neuroendocrine Tumors
• Acromegaly

By Application

• Hospital
• Pharmacy

Global Lanreotide Market by Region